Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now carried by Tesco, the UK’s largest retailer. This expands C-Scrub’s UK retail footprint, increasing visibility and accessibility via Tesco’s nationwide stores and online platform, and supports future portfolio rollout in Europe.
Cosmos Health (NASDAQ:COSM) exhibited at World Health Expo Dubai 2026 (Feb 9–12) to showcase its expanding portfolio of proprietary nutraceutical and wellness brands, including Sky Premium Life, NOOR, C-Scrub, and Mediterranation.
The company highlighted vertical manufacturing, expanded distribution in Europe, Middle East and North America, and ongoing discussions with potential partners across Asia and Latin America.
Cosmos Health (NASDAQ:COSM) expanded its digital assets program by purchasing $500,000 of Bitcoin, bringing total cryptocurrency investments to $2.5 million. Ethereum remains a key pillar while the company will selectively evaluate other cryptocurrencies based on market conditions and strategic fit.
The purchase was executed at an average price below $70,000 per Bitcoin, reflecting a disciplined, opportunistic capital deployment approach aligned with long-term financial objectives.
Cosmos Health (NASDAQ:COSM) reported continued operational growth at Cosmofarm in 2025, adding nearly 100 new pharmacy customers (about a 20% weighted increase in active customer base). The business saw annual revenue per customer +12% and profitability per customer +14%, driven by improved route density, order execution and operational leverage. Cosmofarm added three new delivery routes in Attica and is upgrading a 29,000-square-foot Athens facility with expanded distribution and temperature-controlled storage. The company continues multi-year investments in ROWA and A-frame robotic systems and is executing an additional ~$1 million capital program to expand robotic capacity, supporting an incremental annual revenue potential of approximately $40 million as volumes scale.
Cosmos Health (NASDAQ:COSM) announced that Zacks Small-Cap Research initiated coverage on January 13, 2026, assigning a $4.50 per share valuation based on a five-year DCF using a 20% discount rate and a 2% terminal growth rate. Zacks projects revenue growth from $64.4M in 2025 to $98.6M in 2026 and to over $130M in 2027, driven by higher-margin pharmaceuticals, nutraceutical brands, telehealth, and Cloudscreen AI-enabled R&D. The report cites Cosmos Health’s U.S. expansion (ZipDoctor, Sky Premium Life), a disclosed $300M financing facility, ETH purchases, and record Q3 2025 revenue and improved adjusted EBITDA as supporting factors. Cosmos disclosed it paid Zacks for the report.
Cosmos Health (NASDAQ:COSM) announced that its subsidiary Cana Laboratories signed a manufacturing and supply agreement to produce the finished pharmaceutical PathMuscle for Libytec Pharmaceutical S.A., the product's exclusive distributor in Greece, effective Jan 5, 2026. Cosmos Health will handle end-to-end production, quality control, and product release for multiple oral presentations (film-coated and soluble tablets).
The deal includes a firm minimum of 591,500 units and expected cumulative volumes of over 1.2 million units across five years, intended to improve capacity utilization and provide enhanced revenue visibility, subject to market demand and commercial performance.
Cosmos Health (NASDAQ:COSM) reported Q3 revenues above $17 million and is accelerating a platform strategy that reduces tariff exposure by adding U.S. manufacturing capacity. Through an agreement with New Jersey-based DolCas Biotech, Cosmos plans domestic production to avoid import duties and strengthen supply-chain resilience.
The company leverages European GMP-certified manufacturing, existing distribution across Europe and the U.K., and a growing healthcare services arm to smooth revenue. CEO Greg Siokas has increased insider purchases, signaling management alignment with the strategy.
Cosmos Health (NASDAQ:COSM) reported a record quarter with revenue north of $17 million and expanding gross profit margins, marking the company's highest revenue in history on December 19, 2025. Management highlights operational scale across pharmaceuticals, nutraceuticals and healthcare services, plus manufacturing compliant with European GMP and established distribution.
The company completed acquisitions of ZipDoctor and Cloudscreen, CEO Greg Siokas continued share purchases, and Cosmos disclosed a $500,000 Ethereum purchase, bringing total digital investments to over $2 million under a $300 million facility.
Cosmos Health (NASDAQ:COSM) announced a long-term strategic partnership with Prime Ledger to digitally transform its financial operations and tokenize intellectual property. The agreement centers on Prime Ledger assisting to manage Cosmos Health’s $300,000,000 treasury, implementing controls, protocols, and reporting for Digital Asset Treasury (DAT) management, and deploying a token issuance platform for high-value IP assets. The collaboration includes integration with Conduit Network to consolidate on-chain and off-chain data for financial reporting, compliance, and real-time analytics. The initial phase begins in Q4 2025 and will focus on strategy, regulatory mapping, and platform architecture.
Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas increased his stake during 2025, adding 3,398,055 shares year-to-date, including 301,101 shares bought between Nov 19–28, 2025. Following these purchases, his total ownership stands at 6,459,985 shares. The company noted record-breaking Q3 2025 results across revenue, gross profit, and gross margins but said its valuation remains under pressure. The release directs investors to Form 4 filings for transaction-level details such as ownership form, dates, amounts, and prices.